Unlike many conventional cancers with preferential patterns of oncogenic genetic alterations, TRK fusions resulting from NTRK1/2/3 genetic alterations drive oncogenic transformations in more than 20 different malignancies over diverse tissue/cell lineages, in both children and adults. A recent "basket" study of larotrectinib, a TRK inhibitor, has demonstrated significant efficacy in TRK fusion-positive tumors of all types from infants to the elderly. Here, we discuss the larotrectinib study and perspectives and challenges in developing "tumor-agnostic" targeted therapies in rare tumors.
Background
Traditionally, cancers are classified and treated based on their pathologic classification and tissue of origin. Advances in sequencing technology and large-scale cancer genomics effort (e.g., the International Cancer Genome Consortium and The Cancer Genome Atlas (TCGA) have identified many targetable driver genetic alterations across different tumor types and have shifted the cancer sub-classification based on driver genetic alterations. For example, lung adenocarcinomas are further sub-classified by KRAS and EGFR mutations and ALK and ROS1 translocation. Most "driver" genetic alterations are preferentially found in certain cell/tissue lineages. For example, the BRAF V600 mutation occurs at high frequencies in specific tumor types, e.g., melanoma, thyroid cancer, hairy cell leukemia, Langerhans cell histiocytosis, and colorectal cancer, and at significantly lower frequencies in other tissue lineages. The responses to BRAF V600 -targeted therapies are not uniform, with some cancer types (e.g., colorectal cancer) exhibit tissue lineage-specific primary resistance [1] [2] [3] , underlining the importance of the tissue lineage-specific cellular context.
TRK fusions are rare but drive oncogenesis in diverse tissue lineages
The NTRK1, NTRK2, and NTRK3 genes, encoding the tropomyosin receptor kinases (TRK), TRKA, TRKB, and TRKC, respectively, are receptor tyrosine kinases that are normally expressed in the nervous system [4] . Physiologically, TRK receptor tyrosine kinases are activated by binding of mature neurotrophins, which mediate neuronal survival and synaptic plasticity in the central nervous system [4] . NTRK genetic alterations (e.g., translocations) resulting in TRK fusion proteins can lead to ligand-independent activation of TRK kinases and drive oncogenic transformation [5] [6] [7] . To date, TRK fusions are found in more than 20 different tumor types. With the exception of several rare tumor types (e.g., secretory breast carcinoma, mammary analog secretory carcinoma, congenital fibrosarcomas, and congenital mesoblastic nephroma), the majority of the TRK fusions occur in low frequencies in a variety of common cancers over a diverse tissue/cell lineages (e.g., lung adenocarcinoma, sarcoma, acute myeloid leukemia, colorectal cancer) [6, 7] (Table 1 ). The rarity of TRK fusions and the heterogeneity of tumor types present incredible challenges to clinically evaluate TRK inhibitors. Diagnostically, because of large introns, these fusions are difficult to detect using multiplex targeted exome capture panels (e.g., FoundationOne®, MSK-IMPACT™). NTRK1 (2/185) RNA-seq (TCGA and other) [27] NTRK1 (3/115) Targeted NGS [28] Brain low-grade glioma NTRK2 (2/461) RNA-seq (TCGA) [21] Pediatric DIPG and non-brainstem high-grade glioma NTRK1 (3/127) RNA-seq, whole-genome seq [29] NTRK2 (3/127) RNA-seq, whole-genome seq [29] NTRK3 (2/127) RNA-seq, whole-genome seq [29] Head and neck squamous cell carcinoma NTRK2 (1/411) RNA-seq (TCGA) [21] NTRK3 (1/411) RNA-seq (TCGA) [21] Congenital mesoblastic nephroma NTRK3 (5/6) RT-PCR, FISH [30] NTRK3 ( NTRK1(pediatric) (1/27) Targeted NGS [44] NTRK3(radiation-associated) (2/26) RNA-seq [45] NTRK3(radiation-associated) (9/62) RNA-seq [46] NTRK3(sporadic) (3/151) RNA-seq [46] NTRK3(pediatric) (6/27) Targeted NGS [44] TRK inhibitor larotrectinib demonstrates efficacy in a basket trial
Recently, Drilon and colleagues reported a phase I/II clinical trial to evaluate the safety and efficacy of larotrectinib, a highly selective small-molecule inhibitor of all three TRK proteins, using a novel "basket" trial design that enrolled patients based on NTRK genetic alterations regardless of age or tumor types [8] . A total of 55 patients (ages 4 months-76 years old) with 16 different tumor histologies were treated on three protocols, and the results were pooled. The investigators found that larotrectinib was generally well-tolerated with < 5% treatment-related grade 3 or 4 adverse events. The overall RECIST response rate was 75% (95% confidence interval, 61-85) by independent review and 80% (95% confidence interval, 67-90) by investigator assessment. At 1 year, 71% of patients are with ongoing responses and 55% of patients remain progression-free. The median duration of response and progression-free survival has not been reached after 8.3 and 9.9 months of median follow-up, respectively. Importantly, responses were observed in nearly all tumor types and age groups. Three of the six patients who did not response to larotrectinib (primary resistance) had undetectable TRK proteins by immunohistochemistry (IHC) despite molecularly identified TRK fusion at a screening in local laboratories. In the ten patients who progressed after an initial response for at least 6 months, nine had identifiable secondary resistant mutations in NTRK1 or NTRK3, including substitutions in the solvent front position (NTRK1 G595R or NTRK3 G623R), gatekeeper mutation (NRTK1 F589 L), and the xDFG position NTRK1 G667S or NTRK3 G696A). The acquired resistance mechanisms have been described for other oncogenic kinase-targeted therapies [9] [10] [11] . The next generation of TRK inhibitors is in development to overcome the acquired resistance in TRK [7, 12] (see Table 2 ).
Future perspectives
The study by Drillon et al. [8] comes on the heels of several basket trials, including the AKT inhibitor AZD5363 in AKT1 E17K-mutant tumors [13] , the PD1 inhibitor pembrolizumab in mismatch repair deficient tumors [14] , and the pan-HER kinase inhibitor neratinib in HER2-and HER3-mutant tumors [15] , with variable clinical success. This current study provides a compelling case for tumor-agnostic, molecular-driven "basket" approaches for clinical investigations of rare driver mutations across diverse tumor types. It paves a clinical pathway to effective therapeutics for patients with rare tumors and rare driver mutations. In addition to larotrectinib, there is a variety of TRK inhibitors currently in clinical development (Table 1) , including next-generation TRK inhibitors that can overcome acquired resistance (e.g., LOXO-195, TPX-0005). Despite the early clinical success with new generations of TRK inhibitors and novel trial design, the challenges remain for real-time identification of rare TRK fusions. What would be the ideal diagnostics methodology? DNA-based next-generation sequencing (NGS) assays have relatively high false-negative and false-positive rate and do not identify novel fusions. RNA-based NGS assays (e.g., Archer Dx) can detect novel fusions and has reasonable sensitivity. However, both DNA-and RNA-based NGS assays can be costly and effort intensive. Alternatively, IHC of TRK is a sensitive and efficient method for identification of TRK expression [16, 17] . Nevertheless, it would not readily discriminate TRK fusion arising through genetic alterations where With a shifting paradigm of identifying genetic alterations in a tumor-agnostic manner, the development of a single assay that can identify multiple types of actionable genetic alterations would be paramount. In the meantime, TRK IHC would be a reasonable initial diagnostics for rare tumors where TRK fusions are frequent, and possibly common tumors where driver mutations are absent.
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